Document is current
Any future updates will be listed below
-
Authors
Piekarska, Agnieszka https://orcid.org/0000-0002-1593-8005
Abouqateb, Mouad
Boreland, William
Peczynski, Christophe
Zaucha, Jan Maciej
Kröger, Nicolaus https://orcid.org/0000-0001-5103-9966
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Ciceri, Fabio
Schroeder, Thomas
Luft, Thomas https://orcid.org/0000-0002-0387-1640
Passweg, Jakob https://orcid.org/0000-0001-7092-3351
Kunadt, Desiree
Stelljes, Matthias https://orcid.org/0000-0002-9331-5145
Blau, Igor Wolfgang
Platzbecker, Uwe https://orcid.org/0000-0003-1863-3239
Yakoub-Agha, Ibrahim https://orcid.org/0000-0003-4524-8782
Blaise, Didier https://orcid.org/0000-0002-5684-9447
Raiola, Anna Maria
Tischer, Johanna https://orcid.org/0000-0003-1821-1976
Wagner-Drouet, Eva Maria https://orcid.org/0000-0002-0728-2253
Winkler, Julia
Schmid, Christoph
Wulf, Gerald
Edinger, Matthias
Maertens, Johan https://orcid.org/0000-0003-4257-5980
Stölzel, Friedrich https://orcid.org/0000-0003-0653-5332
Vydra, Jan https://orcid.org/0000-0002-4274-3895
Zak, Pavel
Moiseev, Ivan
Schoemans, Hélène https://orcid.org/0000-0002-7568-8239
Penack, Olaf https://orcid.org/0000-0003-4876-802X
Peric, Zinaida https://orcid.org/0000-0001-9458-8025
- License Information
-
More Information
Article History
Received: 14 March 2025
Revised: 5 July 2025
Accepted: 4 August 2025
First Online: 11 September 2025
Competing interests
: Nothing to declare for this topic, except potential relatedness to HCT/GVHD topics: AP has received honoraria or travel support from Alexion, AstraZeneca, Astellas, Gilead, MSD, Novartis, Pierre Fabre, Pfizer, Sanofi, and the EBMT (European Society for Blood and Marrow transplantation) which not directly related to this work. NK received honorarium from Mallinckrodt, Novartis, Kit/Gilead, BMS, Takeda, Medac, Neovii, Sanofi IYA: received honoraria from Gilead/Kite, BMS, Novartis and AstraZeneca. EMW-D reports personal fees from Novartis, Takeda, Janssen, Incyte, MEDAC. FS has received travel support from Janssen and Medac, honoraria from Medac, GWT, Abbvie, Servier and Pierre Fabre and research funding from Medac and Servier. HS reports having received personal fees from Incyte, Janssen, Novartis, Sanofi and from the Belgian Hematological Society (BHS), as well as research grants from Novartis and the BHS, all paid to her institution and not directly related to this work. She has also received non-financial support (travel grants) from Gilead, Pfizer, EBMT and the CIBMTR (Center for International Bone Marrow Transplantation Research). OP has received honoraria or travel support from Gilead, Jazz, MSD, Neovii, Novartis, Pfizer and Therakos. He has received research support from Incyte and Priothera. He is member of advisory boards to Equillium Bio, Jazz, Gilead, Novartis, MSD, Omeros, Priothera, Sanofi, Shionogi and SOBI. RZ reports having received personal fees from Incyte, MNK, Novartis, Sanofi, Medac and Neovii.
